Huadong Medicine (000963) issued an announcement that the company held an annual performance exchange meeting on April 18, 2025.

The company said that it is actively preparing for the listing of Ailahe® and will actively participate in medical insurance negotiations to strive to enter medical insurance as soon as possible.

Bailing Capsules were successfully selected in the national Chinese patent medicine alliance centralized procurement renewal at the end of last year. The winning price adjustment was relatively small. While ensuring the coverage of the core market, it also laid the foundation for subsequent grassroots penetration.

The oral small molecule GLP-1 receptor agonist HDM1002 study achieved the preset test goals, has a good weight loss effect, and has good safety and tolerability. The first subject has been enrolled in the Phase III clinical study of weight management indications. The company's semaglutide injection diabetes indication has been submitted for listing in March 2025 and accepted.

In the field of ADC, the company combines independent research and development with product introduction, and has successively invested in, controlled, and incubated a number of biotech companies with leading technologies to form an ADC global research and development ecosystem. At present, the company has more than 12 ADC pipelines. The company's first independently developed ADC project HDM2005, targeting ROR1, is used to treat advanced malignant tumors. The first subject of the Chinese Phase I clinical trial of this product was enrolled in August 2024, and the first three dose ramps have been completed, and no DLT (dose-limiting toxicity) has occurred.

In terms of domestic medical beauty, new products to be commercialized this year include high-end hyaluronic acid MaiLi Extreme and facial skin management equipment Préime DermaFacial. In addition, the company is confident in the future performance of overseas markets. At present, Sinclair, a wholly-owned subsidiary of the United Kingdom, is actively promoting the overseas registration of medical beauty products, especially the registration and listing of injectable products in potential markets such as the United States.

In 2024, Huadong Medicine achieved revenue of 41.906 billion yuan and net profit attributable to the parent of 3.512 billion yuan.

https://finance.eastmoney.com/a/202504203382043692.html